Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
PRAX Stock Chart & Stats
$275.73
-$2.82(-3.64%)
At close: 4:00 PM EST
$275.73
-$2.82(-3.64%)
Day’s Range― - ―
52-Week Range$26.70 - $286.50
Previous CloseN/A
Volume51.58K
Average Volume (3M)938.42K
Market Cap
$6.90B
Enterprise Value$898.07M
Total Cash (Recent Filing)$267.16M
Total Debt (Recent Filing)$436.00K
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Mar 04, 2026EPS Estimate
-3.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.36
Shares Outstanding25,007,172
10 Day Avg. Volume669,426
30 Day Avg. Volume938,423
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.09
Price to Sales (P/S)161.13
P/FCF Ratio-10.46
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue120.34
Enterprise Value/Gross Profit-3.77
Enterprise Value/Ebitda-3.11
Forecast
1Y Price Target
$419.13Price Target Upside52.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-13.07
Revenue Forecast (FY)$325.93K
Bulls Say, Bears Say
Bulls Say
Efficacy ResultsRelutrigine achieved statistically significant placebo-adjusted seizure reductions of 53% in SCN2A/8A patients, far exceeding expectations.
Market OpportunityThe epilepsy pipeline, despite being overshadowed by the essential tremor asset, presents a substantial opportunity with estimated significant sales by FY36.
Regulatory ApprovalPraxis Precision Medicines announced a positive pre-NDA meeting with the FDA for ulixacaltamide in essential tremor, indicating potential progress towards approval.
Bears Say
Praxis Precision Medicines News
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $26.70 and its highest was $286.50 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Praxis Precision Medicines’s market cap is $6.90B.
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is Mar 04, 2026 which is in 68 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on Nov 05, 2025. The company reported -$3.36 earnings per share for the quarter, beating the consensus estimate of -$3.466 by $0.106.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -3.09.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 25,007,172 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$3.36 in its last earnings report, beating expectations of -$3.466. Following the earnings report the stock price went down -4.14%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Currently, no hedge funds are holding shares in PRAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Praxis Precision Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$419.13 (52.01% Upside)
$419.13 (52.01% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 80%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 23.9%
Last 30 Days ▲ 23.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
255.45%
12-Months-Change
Fundamentals
Return on Equity
-75.20%
Trailing 12-Months
Asset Growth
-4.77%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
PRAX Company Deck
PRAX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in the efficacy of vormatrigine, strong execution of clinical trials, and a robust financial position. However, challenges remain in managing discontinuation rates and background therapy interactions.View all PRAX earnings summariesPRAX Stock 12 Month Forecast
Average Price Target
$419.13
▲(52.01% Upside)
Technical Analysis
ARS Pharmaceuticals
―
AbCellera Biologics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
18.54% Insiders
12.14% Mutual Funds
46.66% Other Institutional Investors
9.56% Public Companies and Individual Investors